Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Steglujan, Ertugliflozin / Sitagliptin, Diabetes Mellitus, Type 2, Date of Authorisation: 23/03/2018, Revision: 4, Status: Authorised
Case Medical Research
doi 10.31525/cmr-12043e3
Full Text
Open PDF
Abstract
Available in
full text
Date
May 7, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Ristfor, Sitagliptin / Metformin Hydrochloride, Diabetes Mellitus, Type 2, Date of Authorisation: 15/03/2010, Revision: 19, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): NovoRapid, Insulin Aspart, Diabetes Mellitus, Date of Authorisation: 07/09/1999, Revision: 29, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Mixtard, Insulin Human (rDNA), Diabetes Mellitus, Date of Authorisation: 07/10/2002, Revision: 18, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Jevtana, Cabazitaxel, Prostatic Neoplasms, Date of Authorisation: 17/03/2011, Revision: 17, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Intelence, Etravirine, HIV Infections, Date of Authorisation: 28/08/2008, Revision: 23, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Mysimba, Naltrexone / Bupropion, Obesity,Overweight, Date of Authorisation: 26/03/2015, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Lumigan, Bimatoprost, Glaucoma, Open-Angle,Ocular Hypertension, Date of Authorisation: 08/03/2002, Revision: 30, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Fexeric, Ferric Citrate Coordination Complex, Hyperphosphatemia,Renal Dialysis, Date of Authorisation: 23/09/2015, Revision: 2, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Olanzapine Glenmark Europe, Olanzapine, Schizophrenia,Bipolar Disorder, Date of Authorisation: 03/12/2009, Revision: 10, Status: Authorised
Case Medical Research
